AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$NGVT

Ingevity (NGVT) Q3 2026 Earnings Call Transcript

Ingevity (NGVT) reported Q3 2026 sales of $305M, down 8% YoY due to divestitures, but up 2% excluding them. Adjusted EBITDA was $108M, down 2%, with margins expanding to 35.4%. EPS rose 24% to $1.63. The company highlighted growth in filtration and water treatment, secured new contracts, and repurchased $39M in shares. Full-year adjusted EBITDA is expected to be $385M-$395M, with sales around $1.1B and EPS of $5.25-$5.45.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 10:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Ingevity (NGVT) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$NGVTNeutralMed
01

Why it matters

Earnings beat on EPS and strong cash flow may stabilize the stock, but declining sales and higher input costs could limit upside.

02

Market read

First-time Q3 earnings disclosure with updated guidance; relevant for traders tracking specialty chemicals and ESG-driven water treatment markets.

03

What to watch

Potential upcoming PFAS reporting requirements in 2027 may drive future demand for Ingevity's filtration solutions.

Relevance 7/10Novelty 7/10Timing: post-earnings release today

Background

The transcript details Ingevity's Q3 performance, segment breakdowns, and outlook for FY2026, highlighting both growth areas and cost pressures.

Company-level read

Ticker impact

$NGVTNeutralMedium confidence
Context

Ingevity reported Q3 2026 results with sales down 8% YoY, adjusted EPS $1.63 and reaffirmed full-year adjusted EBITDA midpoint of $390M.

Expected impact

likely modest pressure as revenue decline offsets earnings beat, with potential slight downside.

Evidence & confidence

Revenue contraction signals demand weakness, while EPS beat and share repurchases provide support; market may price in modest move.

Market effects

Sector

Filtration and advanced polymers segments may see continued investor interest despite short-term sales dip.

Regional

North American automotive demand supports segment, while Europe/China weakness drags overall sales.

Global

Ingevity's PFAS water treatment focus aligns with broader environmental regulatory trends.

Counterpoint

What could challenge this read

The share repurchase program and EBITDA margin expansion could outweigh revenue softness, prompting a buy on dip.

Key entities

  • Company
    Ingevity

    Specialty chemicals firm focused on filtration and advanced polymers.

  • Executive
    David H. Li

    CEO providing commentary on results and outlook.

Read at source← All news

StoryIngevity posts Q3 2026 results with lower sales but higher profit and raises full‑year outlook

Also covered by

3 outlets

Related articles

$NGVTMed

Ingevity (NGVT) Lifted EPS Guidance, Is The Stock Still Cheap?

Ingevity (NGVT) raised its full-year EPS guidance despite lower Q3 sales. The stock has fallen 15.34% in the past week but remains up 25.15% over one year. Analysts estimate fair value at $89, suggesting a 30% undervaluation, though its P/E ratio is higher than industry averages. The company plans $300M in share buybacks by 2027.

finance.yahoo.com
$NGVTHighAI 8/10

Ingevity Q3 Earnings Call Highlights

Ingevity (NGVT) reports Q3 earnings, highlighting growth in hybrid vehicle and filtration markets. CEO Dave Li notes benefits from the hybrid transition and new water treatment contracts. Pavement Technologies sales fell 24% due to divestiture and higher asphalt costs. Advanced Polymer Technologies sales rose 18%. The company narrowed its 2026 adjusted EBITDA outlook to $385M-$395M and expects $1.1B in sales. Ingevity repurchased $39M in shares during Q3.

finance.yahoo.com
$NGVTMed

Ingevity reports third quarter 2026 financial results

Ingevity Corp (NGVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com Ingevity reports third quarter 2026 financial results Third Quarter 2026 Results and Recent Highlights: • Net sales of $305.1 million decreased 8% from prior year; exclu

SEC EDGAR 8-K
$NGVTHigh

Ingevity reports third quarter 2026 financial results

Ingevity reported Q3 2026 net sales of $305.1M, down 8% YoY. Net income rose to $51.1M per diluted share. Adjusted EBITDA fell $108M but margin expanded to 35.4%. The company narrowed its full-year adjusted EBITDA outlook to $385M-$395M. CEO Dave Li cited strong Performance Materials but noted challenges in Pavement Technologies. Ingevity (NYSE: NGVT) plans to host an earnings call on November 5, 2026.

stocktitan.net